Avidity Biosciences (Nasdaq:RNA) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

RNA 주식 개요

바이오 제약 회사인 Avidity Biosciences는 RNA 치료제를 공급하는 회사입니다.

RNA 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	2/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 17.5% 에서 거래

수익은 연간 66.56% 증가할 것으로 예상됩니다.

위험 분석

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 1년 동안 주주가 희석되었습니다.

지난 3개월간 상당한 내부자 매도

최근 3개월간 주가 변동성

Avidity Biosciences, Inc. 경쟁사

Mirati Therapeutics

NasdaqGS:MRTX

US$4.1b

Merus

NasdaqGM:MRUS

US$3.6b

Ultragenyx Pharmaceutical

NasdaqGS:RARE

US$3.4b

Immunovant

NasdaqGS:IMVT

US$3.8b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Avidity Biosciences
과거 주가
현재 주가	US$37.61
52주 최고치	US$42.00
52주 최저치	US$4.83
베타	0.81
11개월 변경	27.45%
3개월 변경 사항	58.69%
1년 변경 사항	222.56%
33년 변화	39.76%
5년 변화	n/a
IPO 이후 변화	31.96%

최근 뉴스 및 업데이트

Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade

Jun 14

Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline

May 19

Recent updates

Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade

Jun 14

Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline

May 19

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Mar 01

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Feb 29

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

Nov 04

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Apr 08

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Nov 17

Avidity Biosciences (NASDAQ:RNA) Is In A Good Position To Deliver On Growth Plans

Jun 07

주주 수익률

	RNA	US Biotechs	US 마켓
7D	-5.9%	-1.3%	0.4%
1Y	222.6%	7.7%	22.9%

수익률 대 산업: RNA 지난 1년 동안 6.7 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: RNA 지난 1년 동안 23.3 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is RNA's price volatile compared to industry and market?
RNA volatility
RNA Average Weekly Movement	12.2%
Biotechs Industry Average Movement	10.5%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

안정적인 주가: RNA 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: RNA 의 주간 변동성( 12% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2012	253	Sarah Boyce	www.aviditybiosciences.com

바이오 제약 회사인 Avidity Biosciences는 RNA 치료제를 공급하는 회사입니다. 이 회사는 이전에는 RNA 치료제로 치료할 수 없었던 질병을 치료하기 위해 고안된 항체 올리고뉴클레오티드 접합체(AOC)를 개발합니다. 희귀 단원성 근육 질환인 근이영양증 1형 치료를 위한 주요 제품 후보인 AOC 1001은 임상 1/2상 시험 중입니다.

Avidity Biosciences, Inc. 기본 사항 요약

Avidity Biosciences 의 수익과 매출은 시가총액과 어떻게 비교하나요?
RNA 기본 통계
시가총액	US$4.07b
수익(TTM)	-US$228.68m
수익(TTM)	US$10.87m

367.4x

P/S 비율

-17.5x

P/E 비율

RNA 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
RNA 손익 계산서(TTM)
수익	US$10.87m
수익 비용	US$210.04m
총 이익	-US$199.16m
기타 비용	US$29.52m
수익	-US$228.68m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-2.15
총 마진	-1,832.24%
순이익 마진	-2,103.78%
부채/자본 비율	0%

RNA 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

RNA 주식 개요

보상

위험 분석

Avidity Biosciences, Inc. 경쟁사

NasdaqGS:MRTX

US$4.1b

NasdaqGM:MRUS

US$3.6b

NasdaqGS:RARE

US$3.4b

NasdaqGS:IMVT

US$3.8b

가격 내역 및 성능

최근 뉴스 및 업데이트

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $400.9 million.

Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade

Avidity Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline

Avidity Biosciences, Inc. Appoints Simona Skerjanec as Board of Directors

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $400.9 million.

Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade

Avidity Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline

Avidity Biosciences, Inc. Appoints Simona Skerjanec as Board of Directors

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1

New minor risk - Insider selling

Director recently sold US$542k worth of stock

Avidity Biosciences, Inc. announced that it has received $400.208766 million in funding

Consensus revenue estimates increase by 140%

Avidity Biosciences Announces Positive Aoc 1001 Long-Term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 Harbor™ Trial

President notifies of intention to sell stock

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Full year 2023 earnings: EPS and revenues miss analyst expectations

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping

Avidity Biosciences, Inc. Plans to Initiate the Global Phase 3 Harbour Trial of AOC 1001 for Adults Living with Myotonic Dystrophy Type 1, in Mid-2024

Avidity Biosciences Reports Positive Data Demonstrating Aoc 1044 Delivers Unprecedented Concentrations of Pmo in Muscle Following A Single Dose in Healthy Volunteers from Phase 1/2 Explore44™ Trial for Duchenne Muscular Dystrophy

Consensus revenue estimates increase by 104%

Avidity Biosciences, Inc. announced that it expects to receive $39.999993 million in funding from Bristol-Myers Squibb Company

Consensus revenue estimates increase by 17%

Price target increased by 10% to US$40.80

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

Avidity Biosciences, Inc. Presents New Data Regarding Its Clinical Study of AOC 1001 for Adults with Myotonic Dystrophy Type 1

Price target increased by 10% to US$40.80

Consensus revenue estimates increase by 11%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Provides an Update to the Status of the Partial Clinical Hold Related to Its AOC 1001 Product Candidate

Consensus revenue estimates increase by 11%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Price target decreased by 7.8% to US$40.57

Full year 2022 earnings released: US$3.34 loss per share (vs US$2.85 loss in FY 2021)

Chief Scientific Officer exercised options and sold US$224k worth of stock

Avidity Biosciences, Inc. Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

President notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$208k worth of stock

Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

Chief Scientific Officer exercised options and sold US$831k worth of stock

Price target increased to US$44.00

Avidity Biosciences, Inc. Announces Positive AOC 1001 Phase 1/2 Marina(Tm) Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Announces Planned Explore44 Trial of AOC 1044 in Healthy Volunteers and Participants with Duchenne Muscular Dystrophy

Avidity Biosciences, Inc. Announces Phase 1/2 EXPLORE44 Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping

Avidity Biosciences Announces the Phase 1/2 Fortitude(Tm) Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences, Inc. Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial

Avidity slips 20% as FDA places lead asset on partial clinical hold

President exercised options and sold US$1.1m worth of stock

President notifies of intention to sell stock

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Avidity Biosciences, Inc. Enrolls Patients in the Marina(Tm) Open-Label Extension Study

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Avidity stock rises amid Chardan starting coverage with Buy

Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides

Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 2000 Growth Index